T. Yu. Yafoshkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
T. Yu. Yafoshkina has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Pavel A. Zharkov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
7 shared publications Т. Ю. Яфошкина
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
5 shared publications- Daria V. Fedorova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
3 shared publications - Dmitry B. Florinskiy
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
3 shared publications - Elena A. Seregina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
3 shared publications - Alexander V. Poletaev
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 73-79
Pharmacokinetic parameters and clinical experience with perioperative continuous infusion of coagulation factor VIII and IX concentrates in children with hemophilia A and B
Introduction . Сontinuous infusion of factor concentrate makes it possible to achieve stable activity of the deficient factor over a long period of time and appears to be an attractive alternative to bolus administration of concentrate as part of perioperative prophylaxis. The aim of the study – evaluation of pharmacokinetic parameters when using continuous factor infusion VIII and IX concentrates in children with hemophilia A and B in the perioperative period in real clinical practice. Materials and methods . A retrospective analysis of medical records data from children with hemophilia A and B who underwent surgical treatment with continuous infusion of factor VIII concentrate was performed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 2015 to 2024. The following pharmacokinetic parameters were also assessed during administration (ACL TOP 700): activity of factors VIII and IX before the administration of concentrate, 30 min after the administration of the concentrate dose and the start of surgery, at finish of the surgery and also every 24 h from the time of surgery until the factor infusion was stopped (single-stage clotting method for determining HemosIL, Instrumentation Laboratory, USA), activated partial thromboplastin time and thromboelastogram. An assessment of bleeding, the presence of an inhibitor to the factor and thrombosis in the early postoperative period was carried out. Results . The study included 5 patients with hemophilia A and 2 patients with hemophilia B. Before surgery, all patients received bolus infusion at a dose of 1000 to 5000 IU with subsequent transition to continuous factor infusion at a median dose of 5 IU/kg/h (range – 3.5 to 9,0 IU/kg/h). All patients had stable pharmacokinetic parameters; the activity of the deficient factor was in the expected range. No patient had complications of surgery with bleeding or thrombosis. Conclusions . In real clinical practice, when using continuous infusion of factor VIII concentrate at a dose of 3,5–9,0 IU/kg/h, stable pharmacokinetic parameters are achieved, allowing its use in children when planning perioperative management.
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 73-79
Open AccessPharmacokinetic parameters and clinical experience with perioperative continuous infusion of coagulation factor VIII and IX concentrates in children with hemophilia A and B
Introduction . Сontinuous infusion of factor concentrate makes it possible to achieve stable activity of the deficient factor over a long period of time and appears to be an attractive alternative to bolus administration of concentrate as part of perioperative prophylaxis. The aim of the study – evaluation of pharmacokinetic parameters when using continuous factor infusion VIII and IX concentrates in children with hemophilia A and B in the perioperative period in real clinical practice. Materials and methods . A retrospective analysis of medical records data from children with hemophilia A and B who underwent surgical treatment with continuous infusion of factor VIII concentrate was performed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 2015 to 2024. The following pharmacokinetic parameters were also assessed during administration (ACL TOP 700): activity of factors VIII and IX before the administration of concentrate, 30 min after the administration of the concentrate dose and the start of surgery, at finish of the surgery and also every 24 h from the time of surgery until the factor infusion was stopped (single-stage clotting method for determining HemosIL, Instrumentation Laboratory, USA), activated partial thromboplastin time and thromboelastogram. An assessment of bleeding, the presence of an inhibitor to the factor and thrombosis in the early postoperative period was carried out. Results . The study included 5 patients with hemophilia A and 2 patients with hemophilia B. Before surgery, all patients received bolus infusion at a dose of 1000 to 5000 IU with subsequent transition to continuous factor infusion at a median dose of 5 IU/kg/h (range – 3.5 to 9,0 IU/kg/h). All patients had stable pharmacokinetic parameters; the activity of the deficient factor was in the expected range. No patient had complications of surgery with bleeding or thrombosis. Conclusions . In real clinical practice, when using continuous infusion of factor VIII concentrate at a dose of 3,5–9,0 IU/kg/h, stable pharmacokinetic parameters are achieved, allowing its use in children when planning perioperative management.
- Open Access
- 15 October 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 130-137
Post-thrombotic syndrome in children with symptomatic deep vein thrombosis
Deep vein thrombosis (DVT) is an increasingly common diagnosis in pediatric inpatients. Approximately 85% of DVTs of extremities are associated with the use of a central venous catheter (CVC). CVC-related thrombosis and non-CVC-related thrombosis differ in their pathophysiology and patient characteristics. We thought it worthwhile to try and analyze whether there was an association between these parameters and further development of complications, namely, post-thrombotic syndrome (PTS). Thus, we aimed to evaluate differences in patient characteristics as well as in the frequency and severity of PTS in children with symptomatic CVC-related and non-CVC-related thrombosis. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We retrospectively analyzed medical records of patients aged 0 to 18 years (at the time of thrombosis) who had undergone treatment at the Center between 2013 and 2023 and selected patients with verified symptomatic DVT of the upper or lower extremity. The patients were divided into 2 groups: patients with CVC-related thrombosis (group 1) and patients with non-CVC-related thrombosis (group 2). Then we analyzed data on PTS in these patients collected during consultations with a hematologist at the Center or via a phone interview. PTS was evaluated using the Russian versions of the Manco–Johnson Instrument (MJI), the Modified Villalta Scale (MVS) and the Clinical Assessment of PTS (CAPTSure) (see the supplementary materials). The statistical significance of differences between the groups was assessed using Chi-square test or, if the expected values in a table were less than 5, using Fisher’s exact test. The study included 47 patients with symptomatic DVT: 17 patients with CVC-related DVT and 30 patients with non-CVCrelated DVT. The patients with CVC-related DVT were found to be younger at the time of thrombosis (median age: 4.1 years (range: 0–17 years) in group 1 versus 15.5 years (range: 3–17 years) in group 2; р < 0.001) and were followed up for longer periods of time (median follow-up time: 5 years (range: 0.5–15 years) in group 1 versus 1 year (range: 0.5–7.5 years) in group 2; р = 0.001). Recanalization at 3 months after DVT was better in the patients with non-CVC-related DVT (50% of the patients in group 1 versus 93% of the patients in group 2; р = 0.002). The overall frequency of PTS was 87% in accordance with MVS/ MJI and 68% as per CAPTSure. The frequency of PTS in the groups was comparable: there were 13 (76%) patients with PTS in the CVC-related thrombosis group and 28 (93%) patients in the non-CVC-related thrombosis group; р = 0.2). The patients with non-CVC-related DVT were found to have more severe PTS more often: 44% of the patients with moderate PTS in the non-CVCrelated DVT group versus 23% of the patients with moderate PTS and CVC-related DVT; р = 0.2. However, these differences did not turn out to be statistically significant. Thus, there were no statistically significant differences in either the frequency or severity of PTS between the two groups. In this study, the overall frequency of PTS in the patients with symptomatic DVT was rather high but the majority of the children in both groups had mild PTS. Still, since PTS is a late complication, it is important to continue patient follow-up to monitor symptoms and severity of chronic venous insufficiency over time.
- 15 October 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 130-137
Open AccessPost-thrombotic syndrome in children with symptomatic deep vein thrombosis
Deep vein thrombosis (DVT) is an increasingly common diagnosis in pediatric inpatients. Approximately 85% of DVTs of extremities are associated with the use of a central venous catheter (CVC). CVC-related thrombosis and non-CVC-related thrombosis differ in their pathophysiology and patient characteristics. We thought it worthwhile to try and analyze whether there was an association between these parameters and further development of complications, namely, post-thrombotic syndrome (PTS). Thus, we aimed to evaluate differences in patient characteristics as well as in the frequency and severity of PTS in children with symptomatic CVC-related and non-CVC-related thrombosis. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We retrospectively analyzed medical records of patients aged 0 to 18 years (at the time of thrombosis) who had undergone treatment at the Center between 2013 and 2023 and selected patients with verified symptomatic DVT of the upper or lower extremity. The patients were divided into 2 groups: patients with CVC-related thrombosis (group 1) and patients with non-CVC-related thrombosis (group 2). Then we analyzed data on PTS in these patients collected during consultations with a hematologist at the Center or via a phone interview. PTS was evaluated using the Russian versions of the Manco–Johnson Instrument (MJI), the Modified Villalta Scale (MVS) and the Clinical Assessment of PTS (CAPTSure) (see the supplementary materials). The statistical significance of differences between the groups was assessed using Chi-square test or, if the expected values in a table were less than 5, using Fisher’s exact test. The study included 47 patients with symptomatic DVT: 17 patients with CVC-related DVT and 30 patients with non-CVCrelated DVT. The patients with CVC-related DVT were found to be younger at the time of thrombosis (median age: 4.1 years (range: 0–17 years) in group 1 versus 15.5 years (range: 3–17 years) in group 2; р < 0.001) and were followed up for longer periods of time (median follow-up time: 5 years (range: 0.5–15 years) in group 1 versus 1 year (range: 0.5–7.5 years) in group 2; р = 0.001). Recanalization at 3 months after DVT was better in the patients with non-CVC-related DVT (50% of the patients in group 1 versus 93% of the patients in group 2; р = 0.002). The overall frequency of PTS was 87% in accordance with MVS/ MJI and 68% as per CAPTSure. The frequency of PTS in the groups was comparable: there were 13 (76%) patients with PTS in the CVC-related thrombosis group and 28 (93%) patients in the non-CVC-related thrombosis group; р = 0.2). The patients with non-CVC-related DVT were found to have more severe PTS more often: 44% of the patients with moderate PTS in the non-CVCrelated DVT group versus 23% of the patients with moderate PTS and CVC-related DVT; р = 0.2. However, these differences did not turn out to be statistically significant. Thus, there were no statistically significant differences in either the frequency or severity of PTS between the two groups. In this study, the overall frequency of PTS in the patients with symptomatic DVT was rather high but the majority of the children in both groups had mild PTS. Still, since PTS is a late complication, it is important to continue patient follow-up to monitor symptoms and severity of chronic venous insufficiency over time.
- Open Access
- 9 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 21-27
Long-term consequence of asymptomatic thrombosis in children
Introduction. Over the past 10 years, there has been a 130 % increase in the amount of thrombosis in hospitalized children. The data about frequency, outcomes and long-term complications of incidental thrombosis is usually presented together with symptomatic thrombosis, and the problem of asymptomatic thrombosis seems to be underestimated.Aim to the study – to assess the patient-related characteristics, outcomes of incidental thrombosis in children. To estimate the frequency, severity and risk factors of post-thrombotic syndrome (PTS) after incidental thrombosis. To evaluate the effect of therapy on thrombus resolution and frequency of PTS following asymptomatic deep vein thrombosis (DVT) in children.Materials and methods. We have retrospectively analyzed the medical records of 48 patients from 0 to 17 years (at the time of thrombosis) from 2013 to 2023 of our tertiary care Centre with objectively confirmed asymptomatic DVT of upper or lower extremity. All patients were divided into 2 groups: patients, who did not receive antithrombotic treatment (G1) and who assessed therapy (G2). Then we analyzed the data of PTS assessment in these patients. PTS was measured using Manco–Jonson Instrument (MJI), Modified Villalta Scale (MVS), the Clinical Assessment of Post-Thrombotic Syndrome (CAPTSure). Chi-square test was used to assess the statistical significance of differences between groups.Results. 90 % of patients were cancer patients, most of DVTs (96 %) were in the veins of upper extremity, 27 % of thrombosis were occlusive. There were no statistically significant differences between G1 and G2 in thrombus resolution, severity and frequency of PTS. The overall frequency of PTS was 46 % using MVS/MJI and 29 % using CAPTSure. Majority of children had mild PTS, the most common symptom was the presence of collaterals. There was 1 patient with moderate PTS in G2.Conclusion. The overall frequency of PTS in patients with asymptomatic thrombosis was 46 %. However, most patients had mild PTS and slight clinical sings. There were no statistically significant difference in the rate of recanalization at 3 months after thrombosis between patients who received anticoagulant therapy and those who did not. Also, there were no statistically significant differences in the frequency and severity of PTS between groups.
- 9 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 21-27
Open AccessLong-term consequence of asymptomatic thrombosis in children
Introduction. Over the past 10 years, there has been a 130 % increase in the amount of thrombosis in hospitalized children. The data about frequency, outcomes and long-term complications of incidental thrombosis is usually presented together with symptomatic thrombosis, and the problem of asymptomatic thrombosis seems to be underestimated.Aim to the study – to assess the patient-related characteristics, outcomes of incidental thrombosis in children. To estimate the frequency, severity and risk factors of post-thrombotic syndrome (PTS) after incidental thrombosis. To evaluate the effect of therapy on thrombus resolution and frequency of PTS following asymptomatic deep vein thrombosis (DVT) in children.Materials and methods. We have retrospectively analyzed the medical records of 48 patients from 0 to 17 years (at the time of thrombosis) from 2013 to 2023 of our tertiary care Centre with objectively confirmed asymptomatic DVT of upper or lower extremity. All patients were divided into 2 groups: patients, who did not receive antithrombotic treatment (G1) and who assessed therapy (G2). Then we analyzed the data of PTS assessment in these patients. PTS was measured using Manco–Jonson Instrument (MJI), Modified Villalta Scale (MVS), the Clinical Assessment of Post-Thrombotic Syndrome (CAPTSure). Chi-square test was used to assess the statistical significance of differences between groups.Results. 90 % of patients were cancer patients, most of DVTs (96 %) were in the veins of upper extremity, 27 % of thrombosis were occlusive. There were no statistically significant differences between G1 and G2 in thrombus resolution, severity and frequency of PTS. The overall frequency of PTS was 46 % using MVS/MJI and 29 % using CAPTSure. Majority of children had mild PTS, the most common symptom was the presence of collaterals. There was 1 patient with moderate PTS in G2.Conclusion. The overall frequency of PTS in patients with asymptomatic thrombosis was 46 %. However, most patients had mild PTS and slight clinical sings. There were no statistically significant difference in the rate of recanalization at 3 months after thrombosis between patients who received anticoagulant therapy and those who did not. Also, there were no statistically significant differences in the frequency and severity of PTS between groups.
- Open Access
- 17 April 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (1) , 33-40
Efficacy and safety of direct oral anticoagulants in children in real clinical practice
Introduction. As well as standard anticoagulants, direct oral anticoagulants (DOAC) have been approved for treatment of thromboembolism in children, recently. Several clinical trials provide promising data on efficacy and safety of DOAC in children and young adults. But further studies aimed at evaluating the efficacy and safety of these drugs in children and adolescents are still needed.The aim of the study is to evaluate the safety and effectiveness of the use DOACs in children.Materials and methods. We have retrospectively analyzed the medical records of patients (0–17 years) of from 2013 to 2022 at our tertiary care Centre and selected patients, who were treated with apixaban, rivaroxaban or dabigatran for more than 14 days. Patients with arterial thrombosis, children, who were treated with combined anticoagulant therapy and those who were unable for follow-up were excluded. We assessed the rates of bleeding and recurrent venous thromboembolism (VTE).Results. There were 67 patients, who were treated with DOAC in our center. Patients were divided into 2 groups: those, who received prophylactic anticoagulation (group 1 – 6 patients), and patients, who received DOAC therapy after venous thromboembolism (group 2 – 61 patients). The median follow-up time was 46 (25–365) days in the group 1, and 4 months (2 weeks – 36 month) in the group 2. There were no VTE episodes and 1 minor bleeding in group 1, while 1 (2 %) major, 4 (6 %) minor bleeding episodes in group 2. There were 4 (6 %) patients with recurrent VTE in group 2.Conclusion. The majority of patients in this study received rivaroxaban (79 %). We found a moderately increased recurrence rate of VTE, which could be the result of a long follow-up period, and a comparable rate of bleeding, all of which were associated with rivaroxaban therapy. In the future, of particular interest, in our opinion, are prospective studies of DOACs as primary antithrombotic prophylaxis, as well as secondary prophylaxis in the highest-risk groups, and the results of an analysis of their use in real clinical practice.
- 17 April 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (1) , 33-40
Open AccessEfficacy and safety of direct oral anticoagulants in children in real clinical practice
Introduction. As well as standard anticoagulants, direct oral anticoagulants (DOAC) have been approved for treatment of thromboembolism in children, recently. Several clinical trials provide promising data on efficacy and safety of DOAC in children and young adults. But further studies aimed at evaluating the efficacy and safety of these drugs in children and adolescents are still needed.The aim of the study is to evaluate the safety and effectiveness of the use DOACs in children.Materials and methods. We have retrospectively analyzed the medical records of patients (0–17 years) of from 2013 to 2022 at our tertiary care Centre and selected patients, who were treated with apixaban, rivaroxaban or dabigatran for more than 14 days. Patients with arterial thrombosis, children, who were treated with combined anticoagulant therapy and those who were unable for follow-up were excluded. We assessed the rates of bleeding and recurrent venous thromboembolism (VTE).Results. There were 67 patients, who were treated with DOAC in our center. Patients were divided into 2 groups: those, who received prophylactic anticoagulation (group 1 – 6 patients), and patients, who received DOAC therapy after venous thromboembolism (group 2 – 61 patients). The median follow-up time was 46 (25–365) days in the group 1, and 4 months (2 weeks – 36 month) in the group 2. There were no VTE episodes and 1 minor bleeding in group 1, while 1 (2 %) major, 4 (6 %) minor bleeding episodes in group 2. There were 4 (6 %) patients with recurrent VTE in group 2.Conclusion. The majority of patients in this study received rivaroxaban (79 %). We found a moderately increased recurrence rate of VTE, which could be the result of a long follow-up period, and a comparable rate of bleeding, all of which were associated with rivaroxaban therapy. In the future, of particular interest, in our opinion, are prospective studies of DOACs as primary antithrombotic prophylaxis, as well as secondary prophylaxis in the highest-risk groups, and the results of an analysis of their use in real clinical practice.
- Open Access
- 9 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 75-82-82
Thrombophilia in children with venous thrombosis
Introduction. Venous thrombosis is a rare condition in children, but now there is a significant increase in cases among hospitalized children. Thrombosis in children is a multifactorial disorder, there are various risk factors, both inherited and acquired, such as a central venous catheter.The aim of the study is to evaluate the incidence of thrombophilia among patients aged 0 to 18 years after a history of deep vein thrombosis (DVT).Materials and methods. We have retrospectively analyzed the medical records of young patients (0–18 years) of from 2017 to 2021 of the Outpatient Consultative Unit of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and selected patients with objectively confirmed DVT, who were examined to exclude thrombophilia. Patients who did not have a full range of laboratory tests were not accounted for in the study. The patients who had DVT during infancy had additional tests at the age older than one year.All patients were divided into 2 groups: with and without thrombophilia. Chi-square test was used to assess the statistical significance of differences between groups.Results. We found 149 children with DVT: 103 patients were completely investigated for thrombophilia and a follow-up investigation is required for another 46 patients. Among 103 patients we didn’t confirm any prothrombotic condition in 54 of them, and thrombophilia was present in 49 patients. The prevalence of thrombophilia was estimated among children with DVT (n = 103): protein C deficiency – 3 %, antithrombin III deficiency – 4 %, protein S deficiency – 4 %, antiphospholipid syndrome – 1 %, mutation FV Leiden (hetero) – 7 %, FII G20210A (hetero) – 8 %, combined – 8 %, others – 13 % (increased concentration of fVIII, increased concentration of lipoprotein (a), high level of homocysteine).While comparing groups of patients with and without thrombophilia by age and sex, and by various clinical characteristics (localization of thrombus, underline clinical condition and some others) no statistically significant differences were revealed.Conclusion. Thrombophilias contribute to the occurrence of thrombosis in children. Results of thrombophilia screening rarely influence acute treatment decisions, so it is important to understand the limitations of this approach. Nevertheless, in some cases it is important to try to identify children with a tendency to develop thrombosis, since these patients may be candidates for prophylactic anticoagulation in situations of high risk of developing venous thromboembolism.
- 9 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 75-82-82
Open AccessThrombophilia in children with venous thrombosis
Introduction. Venous thrombosis is a rare condition in children, but now there is a significant increase in cases among hospitalized children. Thrombosis in children is a multifactorial disorder, there are various risk factors, both inherited and acquired, such as a central venous catheter.The aim of the study is to evaluate the incidence of thrombophilia among patients aged 0 to 18 years after a history of deep vein thrombosis (DVT).Materials and methods. We have retrospectively analyzed the medical records of young patients (0–18 years) of from 2017 to 2021 of the Outpatient Consultative Unit of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and selected patients with objectively confirmed DVT, who were examined to exclude thrombophilia. Patients who did not have a full range of laboratory tests were not accounted for in the study. The patients who had DVT during infancy had additional tests at the age older than one year.All patients were divided into 2 groups: with and without thrombophilia. Chi-square test was used to assess the statistical significance of differences between groups.Results. We found 149 children with DVT: 103 patients were completely investigated for thrombophilia and a follow-up investigation is required for another 46 patients. Among 103 patients we didn’t confirm any prothrombotic condition in 54 of them, and thrombophilia was present in 49 patients. The prevalence of thrombophilia was estimated among children with DVT (n = 103): protein C deficiency – 3 %, antithrombin III deficiency – 4 %, protein S deficiency – 4 %, antiphospholipid syndrome – 1 %, mutation FV Leiden (hetero) – 7 %, FII G20210A (hetero) – 8 %, combined – 8 %, others – 13 % (increased concentration of fVIII, increased concentration of lipoprotein (a), high level of homocysteine).While comparing groups of patients with and without thrombophilia by age and sex, and by various clinical characteristics (localization of thrombus, underline clinical condition and some others) no statistically significant differences were revealed.Conclusion. Thrombophilias contribute to the occurrence of thrombosis in children. Results of thrombophilia screening rarely influence acute treatment decisions, so it is important to understand the limitations of this approach. Nevertheless, in some cases it is important to try to identify children with a tendency to develop thrombosis, since these patients may be candidates for prophylactic anticoagulation in situations of high risk of developing venous thromboembolism.
- Open Access
- 30 April 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (1) , 45-51
Post-thrombotic syndrome in children (review)
Post-thrombotic syndrome (PTS) is a long-term consequence of deep vein thrombosis. The development of PTS leads to the loss of venous access, cosmetic defects and poor quality of life due to restrictions in physical and/or daily activities. The review contains data on the prevalence, pathogenesis, prognostic factors and evaluation of PTS. Understanding the occurrence and prevention is very serious because if PTS develops after deep vein thrombosis, children can suffer from various physical and social consequences that may last for many years. The review contains data on the prevalence, pathogenesis, risk factors and diagnosis of PTS.
- 30 April 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (1) , 45-51
Open AccessPost-thrombotic syndrome in children (review)
Post-thrombotic syndrome (PTS) is a long-term consequence of deep vein thrombosis. The development of PTS leads to the loss of venous access, cosmetic defects and poor quality of life due to restrictions in physical and/or daily activities. The review contains data on the prevalence, pathogenesis, prognostic factors and evaluation of PTS. Understanding the occurrence and prevention is very serious because if PTS develops after deep vein thrombosis, children can suffer from various physical and social consequences that may last for many years. The review contains data on the prevalence, pathogenesis, risk factors and diagnosis of PTS.
- 28 May 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (3)
EVALUATION OF THE SENSITIVITY AND SPECIFICITY OF THE PEDIATRIC BLEEDING QUESTIONNAIRE IN VARIOUS HEMORRHAGIC DISORDERS
Determination of significant bleeding in the anamnesis is quite difficult, since mild mucocutaneous bleeding can occur both in patients with hereditary bleeding disorders and in healthy people. As a result, there is a growing interest among researchers and clinicians in accurate and objective quantification of hemorrhage symptoms. Objective of the study: to evaluate the effectiveness of the Pediatric bleeding questionnaire as a tool for identifying a group of children requiring further laboratory examination. Materials and methods of research: the study was a retrospective, uncontrolled, comparative, nonrandomized, single-center study. Based on the analysis of the database of the Consultive department of the Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from January 2017 to December 2019, out of the total number of visits to doctors, patients under 18 years old who complained of increased bleeding were selected. The manifestations of hemorrhagic syndrome were evaluated using the pediatric bleeding scale – PBQ (Pediatric Bleeding Questionnaire), followed by a series of laboratory examinations to verify the diagnosis in all children. The sensitivity and specificity of this questionnaire was assessed at various threshold values using the ROC AUC curve, and a comparison of the scores on the scale in patients with different nosologies was made. Results: the study included 346 people, 174 were diagnosed, 172 had no data for coagulopathy/thrombocytopathy found – the patients were considered healthy. The discriminatory ability of the scale under study, studied using the ROC-AUC, was 0,815 (95% CI 0,772–0,858) – satisfactory. With a threshold value of pathological bleeding of 2 points, the sensitivity of the method was 98%, specificity – 12%. The best ratio of sensitivity and specificity (69% and 79%, respectively) was achieved when the threshold value was increased to 4 points. Conclusion: this questionnaire is a convenient addition, with the help of which it is easy to collect a history of bleeding, to assess the severity of bleeding, but it cannot be used as a screening method due to the large number of falsepositive results.
- 28 May 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (3)
EVALUATION OF THE SENSITIVITY AND SPECIFICITY OF THE PEDIATRIC BLEEDING QUESTIONNAIRE IN VARIOUS HEMORRHAGIC DISORDERS
Determination of significant bleeding in the anamnesis is quite difficult, since mild mucocutaneous bleeding can occur both in patients with hereditary bleeding disorders and in healthy people. As a result, there is a growing interest among researchers and clinicians in accurate and objective quantification of hemorrhage symptoms. Objective of the study: to evaluate the effectiveness of the Pediatric bleeding questionnaire as a tool for identifying a group of children requiring further laboratory examination. Materials and methods of research: the study was a retrospective, uncontrolled, comparative, nonrandomized, single-center study. Based on the analysis of the database of the Consultive department of the Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from January 2017 to December 2019, out of the total number of visits to doctors, patients under 18 years old who complained of increased bleeding were selected. The manifestations of hemorrhagic syndrome were evaluated using the pediatric bleeding scale – PBQ (Pediatric Bleeding Questionnaire), followed by a series of laboratory examinations to verify the diagnosis in all children. The sensitivity and specificity of this questionnaire was assessed at various threshold values using the ROC AUC curve, and a comparison of the scores on the scale in patients with different nosologies was made. Results: the study included 346 people, 174 were diagnosed, 172 had no data for coagulopathy/thrombocytopathy found – the patients were considered healthy. The discriminatory ability of the scale under study, studied using the ROC-AUC, was 0,815 (95% CI 0,772–0,858) – satisfactory. With a threshold value of pathological bleeding of 2 points, the sensitivity of the method was 98%, specificity – 12%. The best ratio of sensitivity and specificity (69% and 79%, respectively) was achieved when the threshold value was increased to 4 points. Conclusion: this questionnaire is a convenient addition, with the help of which it is easy to collect a history of bleeding, to assess the severity of bleeding, but it cannot be used as a screening method due to the large number of falsepositive results.